- Home
- NTB vs NNNN Comparison
NTB vs NNNN Comparison
Compare NTB & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTB
- NNNN
- Stock Information
- Founded
- NTB 1858
- NNNN 2021
- Country
- NTB Bermuda
- NNNN Germany
- Employees
- NTB N/A
- NNNN N/A
- Industry
- NTB Commercial Banks
- NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- NTB Finance
- NNNN Health Care
- Exchange
- NTB Nasdaq
- NNNN Nasdaq
- Market Cap
- NTB 1.9B
- NNNN 2.2B
- IPO Year
- NTB 2016
- NNNN 2025
- Fundamental
- Price
- NTB $46.09
- NNNN $22.23
- Analyst Decision
- NTB Hold
- NNNN
- Analyst Count
- NTB 3
- NNNN 0
- Target Price
- NTB $50.67
- NNNN N/A
- AVG Volume (30 Days)
- NTB 238.0K
- NNNN 38.1K
- Earning Date
- NTB 10-28-2025
- NNNN 04-28-2026
- Dividend Yield
- NTB 4.34%
- NNNN N/A
- EPS Growth
- NTB 17.07
- NNNN N/A
- EPS
- NTB 5.27
- NNNN 0.06
- Revenue
- NTB $599,452,000.00
- NNNN $8,185,146.00
- Revenue This Year
- NTB $4.46
- NNNN N/A
- Revenue Next Year
- NTB N/A
- NNNN N/A
- P/E Ratio
- NTB $8.77
- NNNN $399.17
- Revenue Growth
- NTB 4.60
- NNNN 21.95
- 52 Week Low
- NTB $34.77
- NNNN $5.18
- 52 Week High
- NTB $46.92
- NNNN $55.65
- Technical
- Relative Strength Index (RSI)
- NTB 62.61
- NNNN 48.30
- Support Level
- NTB $45.21
- NNNN $12.93
- Resistance Level
- NTB $46.89
- NNNN $25.20
- Average True Range (ATR)
- NTB 1.02
- NNNN 4.22
- MACD
- NTB 0.24
- NNNN 0.79
- Stochastic Oscillator
- NTB 83.32
- NNNN 79.82
About NTB Bank of N.T. Butterfield & Son Limited (The) Voting
Bank of N.T Butterfield & Son Ltd is a full-service bank and wealth manager. It operates the business through three geographic segments, Bermuda, Cayman Islands, the Channel Islands and the UK. The company offers banking services, comprised of retail and corporate banking, and wealth management, which consists of trust, private banking, and asset management. The company generates a majority of its revenue from Bermuda, and the Cayman Islands segments.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.